Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NVG-111 |
Synonyms | |
Therapy Description |
NVG-111 is a bi-specific T-cell engager (BiTE) that binds to Ror1, potentially resulting in enhanced T-cell response against Ror1-expressing tumor cells and decreased tumor growth (PMID: 28811962). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NVG-111 | NVG 111|NVG111 | ROR1 Antibody 7 | NVG-111 is a bi-specific T-cell engager (BiTE) that binds to Ror1, potentially resulting in enhanced T-cell response against Ror1-expressing tumor cells and decreased tumor growth (PMID: 28811962). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04763083 | Phase Ib/II | NVG-111 | First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma | Recruiting | GBR | 0 |